9-氯-7-(2-氯苯基)-5H-嘧啶并[5,4-d][2]苯并氮杂卓 | 76988-39-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 中文名称: 9-氯-7-(2-氯苯基)-5H-嘧啶并[5,4-d][2]苯并氮杂卓
• 英文名称: 9-chloro-7-(2-chlorophenyl)-5H-pyrimido<5,4-d><2>benzazepine
• 英文别名: 9-Chloro-7-(2-chlorophenyl)pyrimido<5,4-d><2>benzazepine；9-Chloro-7-(2-chlorophenyl)-5H-pyrimido(5,4-d)(2)benzazepine；9-chloro-7-(2-chlorophenyl)-5H-pyrimido[5,4-d][2]benzazepine
• CAS: 76988-39-1
• 化学式: C₁₈H₁₁Cl₂N₃
• 分子量: 340.211
• InChiKey: CLYXKIKVKJZIOF-UHFFFAOYSA-N

物化性质

• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  38.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

制备方法与用途

生物活性

Ro 22-3245 是一种具有焦虑作用的化合物。

反应信息

• 作为反应物：
  描述：

  9-氯-7-(2-氯苯基)-5H-嘧啶并[5,4-d][2]苯并氮杂卓 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 以75%的产率得到9-chloro-7-(2-chlorophenyl)-5H-pyrimido<5,4-d><2>benzazepine 6-oxide
  参考文献：
  名称：

  2-苯并ze庚因。5.嘧啶并[5,4-d] [2]苯并ze庚因的合成及其作为抗焦虑药的评价。

  摘要：

  从相应的2-苯并ze庚因-5-酮开始，合成了一系列5H-嘧啶并[5,4-d] [2]苯并ze庚因，并被评估为潜在的抗焦虑药。从该系列中选择的化合物显示出与地西epa不同的药理作用。在抗戊烯四唑试验和[3H]地西ze结合试验中，它们比地西epa更有效，但在斜筛试验中却显示出较小的活​​性。给出了9-氯-7-（2-氯苯基）-5H-嘧啶[5,4-d] [2]苯并ze庚因（7c）的药理数据。讨论了这些潜在抗焦虑剂的构效关系。

  DOI：

  10.1021/jm00365a008
• 作为产物：
  描述：

  2',5-Dichloro-2-<5-(bromomethyl)-4-pyrimidinyl>benzophenone 在 ammonium hydroxide 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 反应 16.0h， 以64.8%的产率得到9-氯-7-(2-氯苯基)-5H-嘧啶并[5,4-d][2]苯并氮杂卓
  参考文献：
  名称：

  2-Benzazepines. 8. Zerovalent nickel mediated biaryl synthesis of an anxiolytic pyrimido[5,4-d][2]benzazepine

  摘要：

  DOI：

  10.1021/jo00176a015

文献信息

• Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
  申请人：Garvey S. David

  公开号：US20050059655A1

  公开（公告）日：2005-03-17

  The invention describes novel nitrosated and/or nitrosylated diuretic compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated diuretic compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one diuretic compound of the invention, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; and (l) treating nephropathy.

  该发明描述了新颖的亚硝基化和/或亚硝酰化利尿化合物或其药用盐，以及包含至少一种亚硝基化和/或亚硝酰化利尿化合物的新型组合物，以及可选地至少一种一氧化氮供体和/或至少一种治疗剂。该发明还提供了包含该发明中至少一种利尿化合物的新型组合物和试剂盒，该利尿化合物可选择地亚硝基化和/或亚硝酰化，并且可选地至少一种一氧化氮供体化合物和/或至少一种治疗剂。该发明还提供了用于(a)治疗由于过多水分和/或电解贮留引起的疾病；(b)治疗心血管疾病；(c)治疗肾血管疾病；(d)治疗糖尿病；(e)治疗由氧化应激引起的疾病；(f)治疗内皮功能障碍；(g)治疗由内皮功能障碍引起的疾病；(h)治疗肝硬化；(j)治疗子痫前期；(k)治疗骨质疏松症；和(l)治疗肾病的方法。
• Nitric oxide enhancing diuretic compounds, compositions and methods of use
  申请人：Garvey S. David

  公开号：US20060189603A1

  公开（公告）日：2006-08-24

  The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia. The nitric oxide enhancing diuretic compounds comprise at least one nitric oxide enhancing group linked to the diuretic compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.

  该发明描述了包含至少一种增强一氧化氮利尿化合物或其药用盐的新型组合物和试剂盒，以及可选地，至少一种增强一氧化氮化合物和/或至少一种治疗剂的试剂盒。该发明还提供了以下方法：(a)治疗由过多水分和/或电解贮留引起的症状；(b)治疗心血管疾病；(c)治疗肾血管疾病；(d)治疗糖尿病；(e)治疗由氧化应激引起的疾病；(f)治疗内皮功能障碍；(g)治疗由内皮功能障碍引起的疾病；(h)治疗肝硬化；(j)治疗子痫前期；(k)治疗骨质疏松症；(l)治疗肾病；(m)治疗外周血管疾病；(n)治疗门静脉高压；(o)治疗中枢神经系统疾病；(p)治疗代谢综合征；(q)治疗性功能障碍；以及(r)高脂血症。增强一氧化氮利尿化合物包括至少一种增强一氧化氮基团，通过碳、氧和/或氮等一个或多个位点与利尿化合物连接，连接通过不能水解的键或基团。
• Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
  申请人：Garvey David S.

  公开号：US20080287407A1

  公开（公告）日：2008-11-20

  The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

  该发明描述了新颖的硝化和/或亚硝化丙酮酸盐及其药用可接受盐，以及包含至少一种硝化和/或亚硝化丙酮酸化合物的新型组合物，以及可选地，至少一种捐赠、转移或释放一氧化氮、刺激内源性一氧化氮合成、提高内源性内皮源性舒张因子水平或是一氧化氮合酶底物的化合物，和/或至少一种治疗剂。该发明还提供了包含至少一种丙酮酸化合物和至少一种捐赠、转移或释放一氧化氮、提高内源性内皮源性舒张因子水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种治疗剂的新型组合物。该发明还提供了包含至少一种丙酮酸化合物的新型试剂盒，该丙酮酸化合物可选地硝化和/或亚硝化，以及可选地至少一种一氧化氮供体和/或至少一种治疗剂。该发明还提供了治疗由氧化应激、糖尿病、缺血后再灌注损伤、组织、器官、器官部分和/或肢体保护引起的疾病的方法。
• Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
  申请人：——

  公开号：US20040229920A1

  公开（公告）日：2004-11-18

  The present invention describes novel nitrosated and/or nitrosylated potassium channel activators, and novel compositions comprising at least one nitrosated and/or nitrosylated potassium channel activator, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one potassium channel activator, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cardiovascular disorders, cerebrovascular disorders, hypertension, asthma, baldness, urinary incontinence, epilepsy, sleep disorders, gastrointestinal disorders, migraines, irritable bowel syndrome and sensitive skin.

  本发明描述了新型的亚硝酸化和/或亚硝基化的钾通道激活剂，以及包括至少一种亚硝酸化和/或亚硝基化的钾通道激活剂的新型组合物，并且，可选地，包括至少一种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种血管活性药物的化合物。本发明还提供了包括至少一种钾通道激活剂和至少一种捐赠、转移或释放一氧化氮、提高内皮源性松弛因子内源水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种血管活性药物的化合物的新型组合物。本发明还提供了用于治疗或预防男性和女性的性功能障碍、增强男性和女性的性反应以及治疗或预防心血管疾病、脑血管疾病、高血压、哮喘、脱发、尿失禁、癫痫、睡眠障碍、胃肠道疾病、偏头痛、肠易激综合征和敏感皮肤的方法。
• Pyrimido-2-benzazepines
  申请人：Hoffmann-La Roche Inc.

  公开号：US04481142A1

  公开（公告）日：1984-11-06

  There is presented compounds of the formula ##STR1## wherein A is selected from the group consisting of ##STR2## R.sub.1 is selected from the group consisting of hydrogen, chlorine, bromine, lower alkyl, the group NR.sub.4 R.sub.5, the group --CH.sub.2 --CO--R.sub.7, the group--NH(CH.sub.2).sub.m NR.sub.8 R.sub.9, hydroxy, lower alkoxy, mercapto and lower alkyl mercapto; R.sub.2 is selected from the group consisting of hydrogen, amino and dilower alkyl amino; R.sub.3 is selected from the group consisting of hydrogen, lower acyloxy and hydroxy; X is selected from the group consisting of hydrogen, halogen, trifluoromethyl, ethyl, .alpha.-hydroxy ethyl and acetyl; Y is hydrogen or halogen; R.sub.4 and R.sub.5 are hydrogen or lower alkyl or together with their co-bonded nitrogen atom form a five to seven membered heterocyclic group; R.sub.7 is selected from the group consisting of hydroxy lower alkoxy and NR.sub.8 R.sub.9 ; R.sub.8 and R.sub.9 are hydrogen or lower alkyl; n is 0 or 1 and m is 1 to 7 with the limitations that (1) at least one of R.sub.1 and R.sub.2 are hydrogen, (2) when R.sub.3 is lower acyloxy or hydroxy, A is the group (a), X is hydrogen, halogen, trifluoromethyl, ethyl or acetyl and R.sub.1 is the group --NH(CH.sub.2).sub.m NR.sub.8 R.sub.9, then R.sub.8 and R.sub.9 are lower alkyl, (3) when A is group (d) and R.sub.1 is the group --NH(CH.sub.2).sub.m NR.sub.8 R.sub.9 then R.sub.8 and R.sub.9 are lower alkyl and (4) when n is 1, R.sub.1 is hydrogen, lower alkyl, lower alkoxy, chlorine, bromine or the group --CH.sub.2 --CO-- R.sub.7 with R.sub.7 as above then A is the group (a) or (b) and the pharmaceutically acceptable salts thereof. The compounds exhibit pharmacological activity as anxiolytics and sedatives. Also presented Are various novel intermediates and processes to produce the above end products.

  该文中介绍了一些化合物，其化学式为##STR1## 其中A从以下组中选择：##STR2## R1从以下组中选择：氢、氯、溴、低碳基、基团NR4R5、基团--CH2--CO--R7、基团--NH(CH2)mNR8R9、羟基、低烷氧基、巯基和低烷基巯基；R2从以下组中选择：氢、氨基和二低烷基氨基；R3从以下组中选择：氢、低酰氧基和羟基；X从以下组中选择：氢、卤素、三氟甲基、乙基、α-羟基乙基和乙酰基；Y为氢或卤素；R4和R5为氢或低烷基，或与它们共键合的氮原子形成五元至七元杂环基团；R7从以下组中选择：羟基低烷氧基和NR8R9；R8和R9为氢或低烷基；n为0或1，m为1至7，限制为：(1)R1和R2中至少有一个为氢；(2)当R3为低酰氧基或羟基时，A为(a)组，X为氢、卤素、三氟甲基、乙基或乙酰基，R1为基团--NH(CH2)mNR8R9，则R8和R9为低烷基；(3)当A为(d)组，R1为基团--NH(CH2)mNR8R9时，则R8和R9为低烷基；(4)当n为1，R1为氢、低烷基、低烷氧基、氯、溴或基团--CH2--CO--R7，其中R7如上所述，则A为(a)或(b)组及其药学上可接受的盐。这些化合物表现出抗焦虑和镇静的药理活性。此外，还介绍了各种新型中间体和生产上述终产品的工艺。